Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration…
Browsing: Bioxytran Inc
Bioxytran, Inc. (OTCMKTS: BIXT) (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health,…
Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial…
Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced…
Company reiterates focus on advancing ProLectin-M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative disease…